---
title: Clinical features, pathophysiology, and management of acute myelopathy following
  CAR T-cell therapy
date: '2024-09-03'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39226460/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240904182947&v=2.18.0.post9+e462414
source: Blood
description: Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the
  treatment of patients with relapsed or refractory hematologic malignancies, but
  it comes with unique toxicities, notably cytokine release syndrome (CRS) and immune
  effector cell-associated neurotoxicity syndrome (ICANS). As experience with CAR
  T-cell therapy grows, distinct and infrequent neurological complications are becoming
  increasingly evident. Recently, reports of acute myelopathy following the administration
  of ...
disable_comments: true
---
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of patients with relapsed or refractory hematologic malignancies, but it comes with unique toxicities, notably cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). As experience with CAR T-cell therapy grows, distinct and infrequent neurological complications are becoming increasingly evident. Recently, reports of acute myelopathy following the administration of ...